Experimental drug cancels effect from key intellectual disability gene in mice

April 27, 2016

MADISON, Wis. -- A University of Wisconsin-Madison researcher who studies the most common genetic intellectual disability has used an experimental drug to reverse -- in mice -- damage from the mutation that causes the syndrome.

The condition, called fragile X, has devastating effects on intellectual abilities.

Fragile X affects one boy in 4,000 and one girl in 7,000. It is caused by a mutation in a gene that fails to make the protein FMRP. In 2011, Xinyu Zhao, a professor of neuroscience, showed that deleting the gene that makes FMRP in a region of the brain that is essential to memory formation caused memory deficits in mice that mirror human fragile X.

The deletions specifically affected neural stem cells and the new neurons that they form in the hippocampus.

Tantalizingly, Zhao's 2011 study showed that reactivating production of FMRP in new neurons could restore the formation of new memories in the mice. But what remained unclear was exactly how the absence of FMRP was blocking neuron formation, and whether there was any practical way to avert the resulting disability.

Now, in a study published on April 27 in Science Translational Medicine, Zhao and her colleagues at the Waisman Center at UW-Madison have detailed new steps in the complex chain reaction that starts with the loss of FMRP and ends up with mice that cannot remember what they had recently been sniffing.

This study's newfound understanding of the biochemical chain of events became the basis for identifying an experimental cancer drug called Nutlin-3, which blocks the reaction.

In the new study, mice with the FMRP deletion took Nutlin-3 for two weeks. When tested four weeks later, they regained the ability to remember what they had seen -- and smelled -- in their first visit to a test chamber.

Statistically, the memory capacities of normal mice and fragile X models that were treated with Nutlin-3 were identical.

Still, many hurdles remain before the advance can be tested on human patients, Zhao says. "We are a long way from declaring a cure for fragile X, but these results are promising."

Fragile X appears after birth, says Zhao. "Parents start to notice something is wrong, but even if they get an accurate diagnosis, there is no treatment at present. I'm encouraged because affecting this gene's pathway does seem to reverse the memory impairment."

The mouse memory test relied on curiosity. "We placed two objects in an enclosure and let the mice run around," Zhao says. "Mice are naturally curious, so they explore and sniff each one. We take them out after 10 minutes, replace one object with a different one, wait 24 hours and put the mouse back in. If the mouse has normal learning ability, it will recognize the new object and spend more time with it. Mice without the FMRP gene don't remember the old object, so they spend a similar amount of time on each one."

The behavioral assessment was done by different people, says Zhao. "First author Yue Li, a postdoctoral researcher at Waisman, ran the test and sent the video to Michael Stockton, an undergraduate working on the project." Stockton timed how and where each mouse was exploring, "but he had no idea which mouse was which," Zhao says. "It was fantastic to see such clear data."

Two other undergraduates, Jessica Miller and Ismat Bhuiyan (who is now in graduate school) and postdoctoral fellows Brian Eisinger and Yu Gao also worked on the study. The Wisconsin Alumni Research Foundation has applied for a patent on the discovery.

Nutlin-3, which can block the last stage of the chain reaction set off by a mutation in the FMRP gene, is in phase 1 trial for the treatment of the eye cancer retinoblastoma. Finding a new use for a drug that is approved, or that like Nutlin-3 and several derivatives, has entered the approval process, may shorten the lengthy FDA process, says Zhao.

The dose used in the trial -- only 10 percent of the dose proposed for cancer chemotherapy -- caused no apparent harm, she says. "We measured body weight and activity. So far, the mice look healthy and happy."

Because more than one-third of fragile X patients are also diagnosed with autism, the study may shed light on that condition.

In any case, it's far too soon to declare victory over fragile X, Zhao stresses. "There are many hurdles. Among the many questions that need to be answered is how often the treatment would be needed. Still, we've drawn back the curtain on fragile X a bit, and that makes me optimistic."
-end-
David Tenenbaum, 608-265-8549, djtenenb@wisc.edu

This research was supported by grants from the National Institutes of Health (R01MH080434, R01MH078972, and R21NS095632, and a Center grant from NIH to the Waisman Center (P30HD03352).

University of Wisconsin-Madison

Related Gene Articles from Brightsurf:

NIH gene therapy startup to increase AAV gene therapy efficiency
Maximizing the efficiency of the adeno-associated virus (AAV) platform for gene therapy is the aim of a new pilot project of the National Institutes of Health (NIH).

Alzheimer's risk gene disrupts endocytosis, but another disease-linked gene could help
MIT researchers find that astrocytes with the risk-increasing APOE4 variant show deficits of key cellular function called endocytosis, but overexpressing another Alzheimer's associated gene, PICALM, overcame the defect

New Human Gene Therapy editorial: Concern following gene therapy adverse events
Response to the recent report of the deaths of two children receiving high doses of a gene therapy vector (AAV8) in a Phase I trial for X-linked myotubular myopathy (MTM).

Gene therapy/gene editing combo could offer hope for some genetic disorders
A hybrid approach that combines elements of gene therapy with gene editing converted an experimental model of a rare genetic disease into a milder form, significantly enhancing survival, shows a multi-institutional study led by the University of Pennsylvania and Children's National Hospital in Washington, D.C.

Unraveling gene expression
EPFL chemists have uncovered the first steps in the process of gene expression by showing how the protein Rap1 pries open the tightly wound, compacted structure of DNA in the cell to gain access to specific genes.

Gene coding error found in rare, inherited gene cof lung-scarring disorder linked to short telomeres
By combing through the entire genetic sequences of a person with a lung scarring disease and 13 of the person's relatives, Johns Hopkins Medicine researchers say they have found a coding error in a single gene that is likely responsible for a rare form of the disease and the abnormally short protective DNA caps on chromosomes long associated with it.

The two faces of the Jekyll gene
Genes which are specific to a species or group of species can reflect important genetic changes within lineages.

Gene therapy vectors carrying the telomerase gene do not increase the risk of cancer
Researchers from the Spanish National Cancer Research Centre (CNIO) have shown in a new study that the gene therapy with telomerase that they have developed, and which has proven to be effective in mice against diseases caused by excessive telomere shortening and ageing, does not cause cancer or increase the risk of developing it, even in a cancer-prone setting.

Blindness gene discovered
Researchers from UNIGE have investigated a recessive genetic disorder that destroys the eyes from developing and results in childhood blindness.

Gene editing just got easier
An international team of researchers has made CRISPR technology more accessible and standardized by simplifying its complex implementation in a way that offers a broad platform for off-the shelf genome engineering.

Read More: Gene News and Gene Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.